
Editorial: Illinois is right to join the fight against genetic data exploitation
Such a possibility is on the table in the wake of the company's bankruptcy proceedings. Illinois, along with 26 other states and the District of Columbia, has asked the courts to prevent it.
As the lawsuit spells out, 23andMe has quite a bit of 'immutable' — meaning unchanging — personal data. For anyone unfamiliar with how it worked, 23andMe sold kits to customers who wanted a variety of genetic testing services, from tracing their ancestry to identifying predispositions to health issues.
This isn't just about your email address. It's your genome — your most personal and unchangeable data — along with family-tree information that can reveal details about relatives too. Genetic data from similar consumer databases has been used to help solve crimes, such as the Golden State Killer case. While that case involved GEDmatch, not 23andMe, it illustrates the extreme sensitivity of this kind of information.
The use of personal data for profit is part of life these days — social media companies leverage your data to sell ads, loyalty programs share your purchase history with advertisers, and many of the 'free' apps people enjoy regularly share GPS location.
If you use one of those apps, you can delete it or stop sharing your information. But you can't change your DNA.
According to the states' lawsuit, many 23andMe customers who signed up before 2022 never explicitly agreed to the sale of their data. Changing terms after the fact, the suit alleges, is misleading and undermines consumer trust.
23andMe, on the other hand, contends that the data sale is legal under bankruptcy law, that users have already agreed to the company's privacy policies, and that even if the company does sell this asset, former customers will receive the same level of protection. But without specific legal safeguards and enforcement mechanisms, that's a promise that may prove difficult to uphold.
Of course, there's always the option not to share your DNA, the safest bet by a mile. Many people have rightly been skeptical about companies having access to this most sensitive information, in spite of the titillating information they offer to provide in exchange.
Still, millions trusted 23andMe with their sensitive data, believing they could explore their roots or health risks without being turned into a commodity. According to news reports, about 2 million people have requested data deletion from 23andMe in just the past two months, signaling widespread alarm over how that data might be used.
That public concern is exactly why strong legal protections matter. Privacy laws in states like Illinois, Texas and New York also generally require specific consent before sharing genetic or health information. Illinois has long been a leader in privacy legislation, and its Biometric Information Privacy Act forbids the sale or exploitation of biometric data.
Thank goodness for that.
For our part, we're glad to see Illinois and neighboring Wisconsin among the states standing up for consumers, who have a right to control how their most intimate biological information is used. The Wall Street Journal reported late Friday that a nonprofit controlled by 23andMe co-founder Anne Wojcicki is set to buy the company, although that would need court approval. Regardless of who ends up controlling 23andMe, the need for vigilance surrounding data privacy remains.
Our bottom line is that our DNA is more than just data, it's our identity, and it deserves protection.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Regeneron Pharmaceuticals, Inc. (REGN) Acquires 23andMe Assets in $256M Deal
We recently compiled a list of Regeneron Pharmaceuticals, Inc. tops our list for being one of the most undervalued healthcare stocks. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most undervalued stocks. It is a leading American biotech company specializing in treatments for serious diseases across ophthalmology, immunology, oncology, and rare conditions. The company is known for integrating genetics and technology into its drug discovery efforts and continues to grow through internal innovation and strategic acquisitions. In a major move, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is acquiring most of 23andMe's assets for $256 million, including its personal genome service, research services, biobank, and associated data. This will expand the business's access to genetic information from 15 million individuals (with 80% consenting to research use), enhancing its existing warehouse of 3 million anonymized samples. The acquisition significantly boosts Regeneron's capabilities in genetics-guided drug development and precision medicine. The vast dataset will help identify new drug targets, refine clinical trial designs, and improve patient stratification. This positions the corporation to lead the integration of real-world genomic data into personalized healthcare. A pharmacist at work in their online pharmacy checking over orders for pharmaceutical products. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) continues to advance its pipeline with FDA priority reviews for Dupixent (bullous pemphigoid) and Linvoseltamab (multiple myeloma), as well as promising late-stage results for EYLEA HD in eye disorders. The firm's focus remains on leveraging data and science to drive innovative, effective therapies. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Washington Post
17-07-2025
- Washington Post
23andMe is out of bankruptcy. You should still delete your DNA.
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it's back with the same person in charge — and I still don't trust it. Nor do the attorneys general of California, North Carolina, Maryland and Connecticut, who each told me they still recommend people delete their accounts. There are ways to do it even if you have forgotten your log-in information. Tell family members, too.
Yahoo
14-07-2025
- Yahoo
23andMe users have until today to file a claim in the DNA company's bankruptcy case. Here's how to do it.
Today is the deadline for customers of the genetic testing company 23andMe to file a claim as part of a restructuring in its bankruptcy case. In filing a claim, eligible customers can seek compensation for suffering financial or other damages due to a 2023 cyberattack that compromised the sensitive personal information of nearly 7 million users. The direct-to-consumer company has customers submit a saliva sample for their DNA to be analyzed for ancestry purposes, family traits or health risks. 23andMe disclosed the data breach in October 2023, acknowledging that it had exposed users' personal information, including names, relationship labels, ancestry reports and percentage of DNA shared with relatives. This resulted in multiple class-action lawsuits. The DNA testing company filed for Chapter 11 bankruptcy protection in the U.S. in March due to low demand for its ancestry kits in the fallout of the breach. 23andMe alerted customers of the July 14 claim deadline back in May, which was set by the U.S. Bankruptcy Court for the Eastern District of Missouri. There are two types of claims that current and former 23andMe customers can file to receive money back: One is related to cybersecurity (Cyber Security Incident Claim), the other is not cybersecurity-related (General Bar Date Package). Eligible customers can submit either claim by following the instructions on this website. The deadline to file both types of claims is today — Monday, July 14, 2025. If it's submitted electronically, the deadline is at 11:59 p.m. CT; if it's submitted by hard copy, the deadline is 4:59 p.m. CT. Cyber Security Incident Claim 23andMe customers who are eligible to submit the Cyber Security Incident Claim electronically or via postal mail have to meet the following criteria: They were a customer of 23andMe between May 1, 2023, and Oct. 1, 2023. They received a notice that their personal information was compromised in the 2023 data breach. The customer 'incurred monetary damages or non-monetary damages' related to the cybersecurity incident. General Bar Date Package For 23andMe customers who believe they have a claim against the company's services, but it isn't cybersecurity-related, they should file a claim electronically or via postal mail under the General Bar Date Package. This could be related to non-cybersecurity issues, like problems with a customer's DNA results or telehealth services. If a 23andMe customer has questions about the claims process, more information can be found here. Customers can also email 23andMeInfo@ or call (888) 367-7556. No. A Chapter 11 bankruptcy filing means the company is restructuring, instead of liquidating its assets. 23andMe announced at the end of June that it has found a buyer, TTAM Research Institute, which is a nonprofit led by 23andMe cofounder and former CEO Anne Wojcicki. 'The transaction remains subject to Bankruptcy Court approval and customary closing conditions,' the company says. The access that current 23andMe customers have remains unchanged. 'There are no changes to how we store, manage or protect customer data,' according to 23andMe. After filing for Chapter 11 bankruptcy, 23andMe received permission from a judge to sell its most valuable asset — customers' DNA data. 'TTAM has affirmed its commitment to comply with 23andMe's privacy policy and applicable law with respect to treatment of customer data,' the company says, acknowledging the potential sale to TTAM Research Institute. A customer's 23andMe DNA data is not protected under the Health Insurance Portability and Accountability Act, known as HIPAA, which is a law that protects a person's private health information from being shared without the person's knowledge or consent. HIPAA only protects that type of information when it's provided to an entity like a hospital system, physician health plans or billing companies that conduct business with them. 23andMe is not subject to HIPAA regulations because it's a direct-to-consumer company outside of the health care realm. The person is treated as a consumer rather than a patient. The company noted in their FAQ for customers that there's an option for them to delete their data and account. Here's how users can delete their account and personal information: Log into your 23andMe account and go to the 'Settings' section of your profile Scroll to a section labeled '23andMe Data' at the bottom of the page Click 'View' next to '23andMe Data' Scroll to the 'Delete Data' section Click 'Permanently Delete Data' Confirm your request: You'll receive an email from 23andMe; follow the link in the email to confirm your deletion request "If a customer opted in to 23andMe Research, their Personal Information will no longer be used in any future research projects," a 23andMe spokesperson told CNET. "Please note, data cannot be removed from research that's already been conducted."